Novel therapeutic strategies in development for prostate cancer

Expert Opinion on Investigational Drugs

Volumn 17, Issue 1, 2008, Pages 13-22

  Harzstark, Andrea L ^a   Ryan, Charles J ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

Adrenal androgens; Atrasentan; Bevacizumab; Calcitriol; Castration resistant prostate cancer; Chemotherapy; GVAX; Immunotherapy; Ipilimumab; Ixabepilone; Phase II; Prostate cancer; Satraplatin; Sipuleucel T

Indexed keywords

ABIRATERONE ACETATE; ANTINEOPLASTIC AGENT; ATRASENTAN; BEVACIZUMAB; CALCITRIOL; CALCITRIOL DERIVATIVE; CAPECITABINE; CB 7630; CISPLATIN; DOCETAXEL; EPOTHILONE DERIVATIVE; ESTRAMUSTINE; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR VACCINE; HYPOPHYSIS HORMONE; IPILIMUMAB; IXABEPILONE; KETOCONAZOLE; MITOXANTRONE; NILUTAMIDE; PLACEBO; PREDNISONE; PROTEIN TYROSINE KINASE INHIBITOR; SAMARIUM; SATRAPLATIN; SIPULEUCEL T; SORAFENIB; STEROID; STRONTIUM; THALIDOMIDE; UNCLASSIFIED DRUG; UNINDEXED DRUG; VITAMIN D DERIVATIVE; MONOCLONAL ANTIBODY; PLATINUM COMPLEX; TAXOID;

ADJUVANT THERAPY; ADVANCED CANCER; AUTOIMMUNITY; BONE MARROW SUPPRESSION; CANCER COMBINATION CHEMOTHERAPY; CANCER HORMONE THERAPY; CANCER IMMUNIZATION; CANCER IMMUNOTHERAPY; CANCER PALLIATIVE THERAPY; CANCER RADIOTHERAPY; CANCER STAGING; CANCER SURVIVAL; CLINICAL TRIAL; COLITIS; COMBINATION CHEMOTHERAPY; DIARRHEA; DRUG DOSE COMPARISON; DRUG FATALITY; DRUG HYPERSENSITIVITY; DRUG INDUCED HEADACHE; DRUG MECHANISM; DRUG MEGADOSE; DRUG PULSE THERAPY; DRUG TARGETING; DYSPNEA; ENZYME INHIBITION; GASTROINTESTINAL TOXICITY; HORMONAL REGULATION; HORMONAL THERAPY; HUMAN; HYPERTENSION; HYPOPITUITARISM; LOW DRUG DOSE; MALE; METASTASIS; MONOTHERAPY; MULTIPLE CYCLE TREATMENT; NAUSEA AND VOMITING; NEPHROTOXICITY; NEUROPATHY; NEUTROPENIA; PERIPHERAL EDEMA; PROSTATE CANCER; PROSTATECTOMY; PROTEINURIA; REVIEW; RHINITIS; SIDE EFFECT; SINGLE DRUG DOSE; SURVIVAL TIME; THROMBOEMBOLISM; DRUG DESIGN; PROSTATE TUMOR; TREATMENT OUTCOME;

ANTIBODIES, MONOCLONAL; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CLINICAL TRIALS AS TOPIC; DRUG DESIGN; HUMANS; MALE; NEOADJUVANT THERAPY; ORGANOPLATINUM COMPOUNDS; PROSTATIC NEOPLASMS; TAXOIDS; TREATMENT OUTCOME;

EID: 38949098245     PISSN: 13543784     EISSN: None     Source Type: Journal    
DOI: 10.1517/13543784.17.1.13     Document Type: Review

References (52)

1. Attard G, Yap TA, Reid AH, et al. Activity, toxicity, and effect on steroid precursor levels of abiraterone (A), an oral irreversible inhibitor of CYP17 (17α hydroxylase/17,20 lyase), in castrate men with castration refractory prostate cancer (CRPC). Prostate Cancer Symposium, Orlando, Florida; 2007 (Abstract)
2. Ryan CJ, Rosenberg J, Lin A, Valiente J, Kim J, Small EJ. Phase I evaluation of abiraterone acetate (CB7630), a 17 alpha hydroxylase C17,20-Lyase inhibitor in androgen-independent prostate cancer (AiPC). J Clin Oncol, ASCO Annual Meeting Proceedings 2007;25(18S):5064 (Abstract)
3. George DJ, Halabi S, Shepard TF, et al. Prognostic significance of plasma vascular endothelial growth factor levels in patients with hormone-refractory prostate cancer treated on cancer and leukemia group B 9480. Clin Cancer Res 2001;7(7):1932-6
4. Bok RA, Halabi S, Fei DT, et al. Vascular endothelial growth factor and basic fibroblast growth factor urine levels as predictors of outcome in hormone-refractory prostate cancer patients: a cancer and leukemia group B study. Cancer Res 2001;61(6):2533-6
5. Hurwitz H, Fehrenbacher L, Novotny W, et al. Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer. N Engl J Med 2004;350(23):2335-42
6. Sandler A, Gray R, Perry MC, et al. Paclitaxel-carboplatin alone or with bevacizumab for non-small-cell lung cancer. N Engl J Med 2006;355(24):2542-50
7. Miller KD, Chap LI, Holmes FA, et al. Randomized Phase III trial of capecitabine compared with bevacizumab plus capecitabine in patients with previously treated metastatic breast cancer. J Clin Oncol 2005;23(4):792-9
8. Reese DM, Fratesi P, Corry M, Novotny W, Holmgren E, Small EJ. A Phase II trial of humanized anti-vascular endothelial growth factor antibody for the treatment of androgen-independent prostate cancer. Prostate J 2001;3(2):65-70
9. Picus J, Halabi S, Rini B, et al. The use of bevacizumab with docetaxel and estramustine in hormone refractory prostate cancer: initial results of CALGB 90006. Proc Am Soc Clin Oncol 2003;22:1578 (Abstract)
10. Ning YM, Arlen P, Gulley JL, et al. A Phase II trial of thalidomide, bevacizumab, and coetaxel in patients with metastatic androgen-independent prostate cancer. J Clin Oncol, ASCO Annual Meeting Proceedings 2007;25(18S):5114 (Abstract)
11. Wood DP Jr, Beaman A, Banarjee M, Powell I, Pontes E, Cher ML. Effect of neoadjuvant androgen deprivation on circulating prostate cells in the bone marrow of men undergoing radical prostatecromy. Clin Cancer Res 1998;4(9):2119-23
12. Chi KN, Chin E, Winquist SL, et al. Multicenter Phase II study of combined docetaxel and neoadjuvant hormone therapy (NHT) prior to prostatectomy for patients with high risk localized prostate cancer: pathologic outcomes and 3-year follow-up analyses. Prostate Cancer Symposium, Orlando, Florida; 2007 (Abstract)
13. Febbo PG, Richie JP, George DJ, et al. Neoadjuvant docetaxel before radical prostatectomy in patients with high-risk localized prostate cancer. Clin Cancer Res 2005;11(14):5233-40
14. O'brien CA, Garzotto M, Higano CS, et al. Predictors of early relapse in high risk prostate cancer patients treated with neoadjuvant mitoxantrone and docetaxel. J Clin Oncol, ASCO Annual Meeting Proceedings 2005;23(16S):4640 (Abstract)
15. Garzotto M, Higano CS, LOWE BA, et al. Neoadjuvant weekly docetaxel and mitoxantrone in patients with high risk localized prostate cancer: a Phase I trial. Proc Am Soc Clin Oncol 2002;21:2434 (Abstract)
16. Friedman JD, Vaishampayan U, Wood D, et al. Neoadjuvant docetaxel and capecitabine in patients with high-risk prostate cancer: final results of a Phase II trial. J Clin Oncol, ASCO Annual Meeting Proceedings 2007;25(18S):5147 (Abstract)
17. Eastham JA, Kelly WK, Grossfeld GD, Small EJ. Cancer and leukemia group B (CALGB) 90203: a randomized phase 3 study of radical prostatectomy alone versus estramustine and docetaxel before radical prostatectomy for patients with high-risk localized disease. Urology 2003;62(Suppl 1):55-62
18. Kibel AS, Rosenbaum E, Kattan MW, et al. Adjuvant weekly docetaxel for patients with high risk prostate cancer after radical prostatectomy: a multi-institutional pilot study. J Urol 2007;5:1777-81
19. Patel AR, Sandler HM, Pienta KJ, et al. Radiation Therapy Oncology Group 0521: a Phase III randomized trial of androgen suppression and radiation therapy versus androgen suppression and radiation therapy followed by chemotherapy with docetaxel/prednisone for localized, high-risk prostate cancer. Clin Genitourin Cancer 2005;4(3):212-14
20. Fizazi Y, Gravis G, Culine S, et al. The GETUG 12 trial, a Phase III randomized trial of docetaxel-estramustine in high-risk localized prostate cancer: clinical design and current status. Prostate Cancer Symposium, Orlando, Florida; 2007 (Abstract)
21. Sternberg CN. Satraplatin in the treatment of hormone-refractory prostate cancer. BJU Int 2005;96(7):990-4
22. Sternberg CN, Whelan P, Hetherington J, et al. Phase III trial of satraplatin, an oral platinum plus prednisone vs. prednisone alone in patients with hormone-refractory prostate cancer. Oncology 2005;68(1):2-9
23. Latif T, Wood L, Connell C, et al. Phase II study of oral bis (aceto) ammine dichloro (cyclohexamine) platinum (IV) (JM-216, BMS-182751) given daily × 5 in hormone refractory prostate cancer. Invest New Drugs 2005;23(1):79-84
24. Petrylak DP, Sartor O, Witjes F, et al. A Phase-III, randomized, double-blind trial of satraplatin and prednisone vs. placebo and prednisone for patients with hormone refractory prostate cancer. Prostate Cancer Symposium, San Francisco, California; 2006 (Abstract)
25. Sternberg CN, Petrylak D, Witjes F, et al. Satraplatin demonstrates significant clinical beriefits for the treatment of patients with HRPC: results of a randomized Phase III trial. J Clin Oncol, ASCO Annual Meeting Proceedings. 2007;25(18S) 5019 (Abstract)
26. Hussain M, Tangen CN, Lara PN Jr, et al. Ixabepilone (epothilone B analogue BMS-247550) is active in chemotherapy-naive patients with hormone-refractory prostate cancer: a Southwest Oncology Group trial S0111. J Clin Oncol 2005;23(34):8724-9
27. Galsky MD, Small EJ, Oh WY, et al. Multi-institutional randomized Phase II trial of the epothilone B analog ixabepilone (BMS-247550) with or without estramustine phosphate in patients with progressive castrate metastatic prostate cancer. J Clin Oncol 2005;23(7):1439-46
28. Smaletz O, Galsky M, Scher HI, et al. Pilot study of epothilone B analog (BMS-247550) and estramustine phosphate in patients with progressive metastatic prostate cancer following castration. Ann Oncol 2003;14(10):1518-24
29. Rosenberg JE, Weinberg VIC, Beer T, et al. NCI 7347: Phase I/II trial of epothilone analog BMS-247550 (ixabepilone), mitoxantrone, and prednisone in hormone refractory prostate cancer patients previously treated with chemotherapy. Prostate Cancer Symposium, Orlando, Florida; 2007 (Abstract)
30. Sanda MG, Ayygari SR, Jaffee EM, et al. Demonstration of a rational strategy for human prostate cancer gene therapy. J Urol 1994;151(3):622-8
31. Carlsson B, Totterman TH, Essand M. Generation of cytotoxic T lymphocytes specific for the prostate and breast tissue antigen TARP. Prostate Cancer Symposium, Orlando, Florida; 2007 (Abstract)
32. Small EJ, Schellhammer PF, Higano CS, et al. Placebo-controlled Phase III trial of immunologic therapy with sipuleucel-T (APC8015) in patients with metastatic, asympromatic hormone refractory prostate cancer. J Clin Oncol 2006;24(19):3089-94
33. Simons JW, Sacks N. Granulocyte-macrophage colony-stimulating factor-transduced allogeneic cancer cellular immunotherapy: the GVAX vaccine for prostate cancer. Urol Oncol 2006;24(5):419-24
34. Warren TL, Weiner GJ. Uses of granulocyte-macrophage colony-stimulating factor in vaccine development. Curr Opin Hematol 2000;7(3):168-73
35. Halabi S, Small EJ, Kantoff PW, et al. Prognostic model for predicting survival in men with hormone-refractory metastatic prostate cancer. J Clin Oncol 2003;21(7):1232-7
36. Simons JW, Small E, Nelson W, et al. Phase II trials of a GM-CSF gene-transduced prostate cancer cell line vaccine (GVAX) demonstrate anti-tumor activity. Proc Am Soc Clin Oncol 2001;20:1073 (Abstract)
37. Simons J, Nelson W, Nemunaitis J, et al. Phase II trials of a GM-CSF gene-transduced prostate cancer cell line vaccine (GVAX) in hormone refractory prostate cancer. Proc Am Soc Clin Oncol 2002;21:729 (Abstract)
38. Small EJ, Higano C, Smith D, et al. A Phase II study of an allogeneic GM-CSF gene-transduced prostate cancer tell line vaccine in patients with metastatic hormone-refractory prostate cancer. Prostate Cancer Symposium, Orlando, Florida; 2005 (Abstract)
39. Cell Genesys: Cell genesys completes patient recruitment for first Phase III clinical trial of GVAX immunotherapy for prostate cancer. 2007 [cited 2007 August 8]; Available from: http://phx.corporate-ir.net/ phoenix.zhtml?c=98399&p=irol-newsArtide&ID=1024159&highlight=
40. Small EJ, Tchekmedyian NS, Rini BI, Fong L, Israel L, Allison JP. A pilot trial of CTLA-4 blockade with human anti-CTLA-4 in patients with hormone-refractory prostate cancer. Clin Cancer Res 2007;13(6):1810-15
41. Fong L, Kavanaugh B, Hou Y, et al. Combination immunotherapy with GM-CSF and CTL-A-4 blockade for hormone refractory prostate cancer: balancing the expansion of activated effector and regulatory T cells. J Clin Oncol, ASCO Annual Meeting. Proceedings 2007;(18S):3001 (Abstract)
42. Gerritsen W, Van Den Eertwegh AJ, De Gruijl TD, et al. A dose-escalation trial of GM-CSF-gene transduced allogeneic prostate cancer cellular immunotherapy in combination with fully human and-CTL4 antibody (MDX-010, ipilimumab) in patients with metastatic hormone-refractory prostate cancer (MHRPC). Prostate Cancer Symposium, Orlando, Florida; 2007 (Abstract)
43. Beer TM, Ryan CW, Venner PM, et al. Double-blinded randomized study of high-dose calcitriol plus docetaxel compared with placebo plus docetaxel in androgen-independent protate cancer: a report from the ASCENT investigators. J Clin Oncol 2007;25(6):669-74
44. Beer TM, Venner PM, Ryan CW, et al. High dose calcitriol may reduce thrombosis in cancer patients. Br J Haematol 2006;135(3):392-4
45. Venner PM, Ryan C, Petrylak DP, et al. Reduced thromboembolic events with DN-101 (high-dose calcitriol) treatment of androgen-independent prostate cancer: hypothesis for a new class of anticoagulants. J Clin Oncol, ASCO Annual Meeting Proceedings 2006;24(18S):4505 (Abstract)
46. Guise TA, Mohammed KS. Endothelins in bone cancer metastases. Cancer Treat Rest 2004;118:197-212
47. Nelson JB, Chin JL, Love W, et al. Results of a Phase III randomized controlled trial ofthe safety and efficacy of atrasentan in men with nonmetastatic hormone-refractory prostate cancer (HRPC). Prostate Cancer Symposium, Orlando, Florida; 2007 (Abstract)
48. Nelson JB, Chin JL, Love W, et al. Results of a Phase III randomized controlled trial of the safety and efficacy of atrasentan in men with nonmetastatic hormone-refractory prostate cancer (HRPC). J Clin Oncol, ASCO Annual Meeting Proceedings 2007;25(18S):5018 (Abstract)
49. Wilhelm S, Chien DS. BAY 43-9006: preclinical data. Curr Pharm Des 2002;8(25):2255-7
50. Dahut WL, Scripture CD, Posadas EM, et al. Bony metastatic disease responses to sorafenib (BAY 43-9006) independent of PSA in patients with metastatic androgen independent prostate cancer. J Clin Oncol, ASCO Annual Meeting Proceedings 2006;24(18S):4506 (Abstract)
51. Steinbild S, Mross F, Morant D, et al. Phase II study of sorafenib (BAY 43-9006) in hormone-refractory patients with prostate cancer: a study of the central European society for anticancer drug research-EWIV (CESAR). J Clin Oncol, ASCO Annual Meeting Proceedings 2006;24(18S):3094 (Abstract)
52. Gerritsen W, Van Den Ertwegh AJ, De Gruijl TD, et al. Biochemical and immunologic correlates of clinical response in a combination trial of the GM-CSF-gene transduced allogeneic prostate cancer immunotherapy and ipilimumab in patients with metastatic hormone-refractory prostate cancer. J Clin Oncol, ASCO Annual Meeting Proceedings 2007;25(18S):5120 (Abstract)